1180 A Study of Predictive Serum Biomarker Candidates to Predict Tumor Volume and Clinical Performance Status Changes

View at publisher Summarise with VIRAT
Authors: Max A. Saint-Germain, Viveka Chinnasamy, Matthias Holdhoff, Chetan Bettegowda, Jordina Rincón-Torroella, Lawrence Kleinberg, Danielle A Bazer, Peng Huang, David Olayinka. Kamson
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Despite great advancements in circulating biomarkers in neuro-oncology, none reliably predict tumor growth and response to dexamethasone (DEX) therapy. Therefore, while most patients receive DEX during their disease course, no objective measures exist to guide DEX dosage and its duration. METHODS: Blood samples from 14 patients were collected before initial radiotherapy and during follow-up. We measured blood BDNF, YKL-40, GFAP, and NSE levels, and paired them with clinical data (KPS, DEX dose) ±7 days, and brain MRI data acquired ±3 days from blood sampling. Edema (EDEM), contrast-enhancement (CE) and necrosis (NEC) were segmented from T2/FLAIR and T1Gd images. Using machine learning, we generated a multivariable model to predict KPS, MRI_CE, MRI_NEC, MRI_EDEM and their combinations. RESULTS: 43 timepoints from 14 patients were used (age ± SD, mean N of samples XX, range, mean follow up ± SD). BDNF, GFAP and NSE (paste these numbers). For KPS prediction, our model (including sex, methylation status, lg2(NSE), GBM diagnosis, DEX dose, and age) had a correlation coefficient of 0.90 (p < 0.0001). MRI_CE+NEC correlated with lg2(GFAP) (r = 0.56, p < 0.0001) and YKL40 (r = 0.50, p = 0.0006); MRI_NEC with lg2(GFAP) (r = 0.53, p = 0.0003) and YKL40 (r = 0.38, p = 0.0123); MRI_EDEM with lg2(GFAP) (r = 0.47, p = 0.0016); and total tumor volume with lg2(GFAP) (r = 0.54, p = 0.0002). CONCLUSIONS: Serum biomarkers, particularly GFAP and YKL40, show promise in predicting tumor volume changes and KPS. However, prospective trials are needed to validate these results in a clinical setting.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Brain Metastases and Treatment Inflammatory Biomarkers in Disease Prognosis

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
230–230
Publication date
26 March 2026
Language
EN